Asia Pacific Embolization Agents Market

Market Introduction

The APAC embolization agents market is analyzed based on the five major countries such as China, Japan, India, Australia, South Korea, and the rest of APAC. The growth of the market in the APAC region is expected to grow at a faster pace owing to factors such as rising prevalence of the brain stroke, coronary artery diseases, heart diseases, increasing surgical procedures, growing number of hospitals and ambulatory surgeries centers, focus by industry players in Japan and developing healthcare infrastructure in India are likely to boost the market growth in forecast period. As per the World Herat Federation, non-communicable diseases, including CVDs, are estimated to account for 87% of total adult deaths in China. China has one of the highest CVD death rates in the world. The burden of cardiovascular diseases is spurred significantly due to high blood pressure; other factors such as the high prevalence of smoking, unhealthy diet has also contributed to the rising incidences of cardiovascular diseases. There are more than 300 million smokers in the country. As the population ages at an ever-faster pace, it is expected that the number of patients with chronic diseases will increase. The incidences of stroke have increased in the past years, and the incidences of abdominal aortic aneurysm have increased in the country, driving the adoption of embolization agents in the forecast period. Given that, the government of China has invested more in the prevention and treatment of non-communicable diseases. Also, the advanced techniques for stroke prevention and treatment procedures have facilitated the standardization of stroke care for physicians and improved their skills across the country. In addition, the robust healthcare infrastructure in the country is facilitating the adoption of advanced technologies. For instance, nearly 7.4% of the 124 hospitals have established stroke units in Beijing. Also, approximately 300 stroke units have been established across the country, driving the market's growth. Moreover, in China, to meet the population's healthcare needs, the country has developed Healthy China 2030. Also, market players are engaged in strategic activities to expand their footprint in the market. For instance, in May 2021, Grand Pharmaceutical and Healthcare Holdings Limited acquired rights to Shenming Medical Technology Co., Ltd.'s innovative thermosensitive embolic agent to treat liver cancer, further expanding the tumor intervention treatment product pipeline. Therefore, owing to the factors mentioned above, the market for the embolization agents to grow significantly in the forecast period

The COVID-19 pandemic has led to a decline in cardiac procedures in Asia Pacific countries. For instance, the number of cardiac surgeries performed between April and July at the All-India Institute of Medical Sciences (AIIMS) dropped by 89.5%. Similarly, Australia has also recorded a reduction in cardiac surgeries. The study reported in Heart, Lung & Circulation showed that from March to June 2020, 136 adults underwent cardiac surgery, representing a 21% drop in operative caseload in Australia. The Further, outbreak has severely affected the medical tourism industry in Asia Pacific and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to underdeveloped healthcare infrastructures in developing countries, restrictions imposed on suppliers by hospitals, decreasing in demand for cardiovascular surgical instruments, etc. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission, which are impacting supply chains and medical device availability in these countries. They have also affected disposable incomes and resulted in unemployment. Furthermore, business strategies such as acquisitions, mergers, and partnerships are adversely affected by the imposition of complete lockdown. However, surge in the pace of vaccination drives and availability of government reimbursement policies for various cardiovascular procedures are expected to normalize the situation in Asia Pacific and will gradually boost the demand for embolization products in the coming years.

Asia Pacific Embolization Agents Strategic Insights

Strategic insights for the Asia Pacific Embolization Agents provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Embolization Agents Report Scope

Asia Pacific Embolization Agents Regional Insights

The geographic scope of the Asia Pacific Embolization Agents refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The embolization agents market in Asia Pacific is expected to grow from US$ 585.86 million in 2021 to US$ 1,022.36 million by 2028; it is estimated to grow at a CAGR of 8.3% from 2021 to 2028. Surge in Incidence of hypertension, obesity, smoking, and alcoholism; hypertension, smoking, alcoholism, and obesity are associated with the development of brain aneurysms. Thus, increasing prevalence of these diseases is likely to fuel the demand for embolization agents market. Kidney cancer is becoming more common in people of all ages, races, and tumor sizes. Hypertension, being overweight, and smoking are all risk factors for kidney cancer. Obesity is associated with high blood pressure, dyslipidemia, diabetes, or insulin resistance, as well as higher fibrinogen and C-reactive protein levels, all of which increase the risk of cardiovascular diseases (CVD) events. Obesity has been associated with a higher risk of high blood pressure, in addition to CVD. Embolizing agents like the Amplatzer Vascular Plug (AVP) was created for peripheral embolization as a modification of the family of Amplatz septal occluders used in the treatment of congenital heart malformations. Thus, increasing prevalence of hypertension, smoking, alcoholism, and obesity requiring mobility assistance is likely to favor the growth of the APAC embolization agents market.

Key Market Segments

Based on product, the market is segmented into coils, beads/particles, plugs, detachable balloons, glue, sponge, liquid embolics, sclerosants, precipitating agents, others. The beads/particles segment held the largest share of the market in 2020. Based on coils the market is divided into detachable coils and pushable coils. The pushable coils segment held the largest share of the market in 2020. Based on beads/particles the market is divided into spherical and non-spherical. The pushable non-spherical segment held the largest share of the market in 2020. Based on application, the market is segmented into neurology, oncology, cardiology, peripheral vascular diseases, and others. In 2020, the oncology segment is likely to hold the largest share of the market. The embolization agents market by end user, is segmented into hospitals, ambulatory surgical centers, cardiac centers, and others. The hospitals segment held the largest share of the market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the embolization agents market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; Boston Scientific Corporation; Cook Medical LLC; DePuy Synthes; KANEKA CORPORATION; Medtronic; Merit Medical Systems Inc; Penumbra, Inc.; Stryker Corporation; and Terumo Corporation among others.

Reasons to buy report

• To understand the Asia Pacific embolization agents market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific embolization agents market
• Efficiently plan M&A and partnership deals in Asia Pacific embolization agents market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific embolization agents market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

ASIA PACIFIC EMBOLIZATION AGENTS MARKET SEGMENTATION

By Product

• Coils
  • Detachable Coils
  • Pushable Coils
• Beads/ Particles
  • Spherical
  • Non-Spherical
• Plugs
• Detachable Balloons
• Glue
• Sponge
• Liquid Embolics
• Sclerosants
• Precipitating Agents
• Others

By

Application

• Oncology
• Neurology
• Urology
• Cardiology
• Peripheral Vascular Diseases
• Others

By

End User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers
• Others  

By Country

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Company Profiles

• Abbott
• Boston Scientific Corporation
• Cook Medical LLC
• DePuy Synthes
• KANEKA CORPORATION
• Medtronic
• Merit Medical Systems Inc
• Penumbra, Inc.
• Stryker Corporation
• Terumo Corporation